Inhibition of CD83 Alleviates Systemic Inflammation in Herpes Simplex Virus Type 1-Induced Behçet’s Disease Model Mouse

Figure 2

Abatacept affected the frequencies of CD83+ cells in normal and BD mice. (a–d) Frequencies of DC costimulatory molecules CD40, CD83, CD80, and CD86 in normal mice treated with Abatacept in the surface of peripheral blood leukocytes were evaluated by FACS analysis ( for each group). (e) Abatacept 2 mg for 1 to 3 days in normal mice was evaluated by FACS analysis ( for each group). (f–i) Frequencies of CD40, CD83, CD80, and CD86 in BD mice treated with Abatacept were evaluated by FACS analysis ( in normal, in BD, and in BD+Abatacept). (j, k) Abatacept treatment decreased the disease severity score and improved symptoms. (l) Representative histograms of CD83+ and CD86+ cell frequencies in PBL of BD mice treated with Abatacept. Regulatory T cells in BD mice were analyzed by FACS analysis. (m–s) Frequencies of CD4+, CD4+Foxp3+, CD4+CD25+, and CD4+CD25+Foxp3+ Treg cells in BDN, BD, and Abatacept-treated BD mice were evaluated by FACS analysis ( in BDN, in BD, and in BD+Abatacept). indicates the number of mice used in each group. The value was determined by Student’s -test. Experiments were performed more than three independent times.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)

(o)

(p)

(q)

(r)

(s)